Andrew Goldsweig to Purinergic P2Y Receptor Antagonists
This is a "connection" page, showing publications Andrew Goldsweig has written about Purinergic P2Y Receptor Antagonists.
Connection Strength
0.665
-
Fath AR, Qureshi B, Aglan A, Altaee O, Mansoor H, Almomani A, Al-Azizi K, Saad M, Goldsweig AM, Jneid H, Elgendy IY. Contemporary Trends in High-Potency P2Y12 Receptor Inhibitor Use Among Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2026 Apr 07; 15(7):e047683.
Score: 0.241
-
Joseph M, Krishna MM, Ezenna C, Pereira V, Ismayl M, Nanna MG, Bangalore S, Goldsweig AM. Short Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis. Am J Cardiol. 2025 Feb 15; 237:17-28.
Score: 0.219
-
Mostafa MR, Eid MM, Awad AK, Takla A, Hassan AR, Katamesh BE, AlBarakat MM, Ziada AR, Mohamed S, Al-Azizi KM, Goldsweig AM. Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. Am J Cardiovasc Drugs. 2024 Jan; 24(1):71-81.
Score: 0.205